Market Newsdesk

Minneapolis, Dec. 03, 2020 (GLOBE NEWSWIRE) — (CLA) CliftonLarsonAllen LLP was named Firm of the Year by Nexia International, a global network of independent accounting and consulting firms. The award recognizes the contributions (CLA) CliftonLarsonAllen LLP has made to the development of Nexia and celebrates its success.

“Receiving this award is an incredible honor,” said CEO Denny Schleper. “Nexia is truly committed to helping its members provide international services to clients in a cohesive, personal, and customized manner.”

In addition, (CLA) CliftonLarsonAllen LLP’s chief global officer, Jeff Kvilhaug, was recognized as Nexian of the Year. This award is given to an individual who is a proactive ambassador and champion within their national, regional, or international markets and made a significant contribution to the wider Nexia network in the previous 12 months. Kvilhaug, who has enjoyed a 36-year career with the firm, also serves on the Nexia Strategy Committee.

“I’m truly humbled by this award,” said Kvilhaug. “And it’s even sweeter to win this in 2020, a year where a pandemic has increased the physical and psychological distance between people across the world. I’m so proud that my fellow teammates have been among the guiding voices throughout Nexia to help bring us all closer together.”

(CLA) CliftonLarsonAllen LLP’s independent membership with Nexia International has always been focused on the idea of global collaboration. Member firms share ideas and thought leadership materials, including webinars on U.S. relief programs and content to help global organizations navigate COVID-19 relief funding. Over the years, (CLA) CliftonLarsonAllen LLP professionals have provided leadership on Nexia International committees and groups. Jen Leary, the firm’s chief strategy officer, serves on the Nexia board of directors and its strategy committee.

“This has been a challenging year for firms of all shapes and sizes, and there’s no doubt that our connection with Nexia helped us all get through it,” said Leary. “We treasure our relationships with the member firms and look forward to them flourishing for years to come.”

Visit CLAconnect.com for more information.

About (CLA) CliftonLarsonAllen LLP

(CLA) CliftonLarsonAllen LLP exists to create opportunities for our clients, our people, and our communities through industry-focused wealth advisory, outsourcing, audit, tax, and consulting services. With more than 6,200 people, 120 U.S. locations and a global affiliation, we promise to know you and help you. For more information, visit CLAconnect.com. Investment advisory services are offered through CliftonLarsonAllen Wealth Advisors, LLC, an SEC-registered investment advisor.

Attachment

• Jeff Kvilhaug

Jackie Kruger
CLA (CliftonLarsonAllen LLP)
612-376-4623
[email protected]

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 62^nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually December 5 – 8, 2020.

ASH 2020 PRESENTA


T


ION DETAILS:

• Oral Presentation Title: Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 UNITY-CLL Study
  • Publication Number: 543
  • Oral Session: 642. CLL: Therapy, excluding Transplantation
  • Session Date and Time: Monday, December 7, 2020; 7:00 AM – 8:30 AM (Pacific Time)
    • Presentation Time: 7:15 AM (Pacific Time)
  • Presenter: John G. Gribben, MD, D.Sc., Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;

• Poster Presentation Title: Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global UNITY-NHL Trial
  • Publication Number: 2934
  • Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
  • Date and Time: Monday, December 7, 2020; 7:00 AM – 3:30 PM (Pacific Time)
  • Presenter: Pier Luigi Zinzani, MD, PhD, Institute of Hematology, “L. e A. Seràgnoli”, University of Bologna, Italy
• Poster Presentation Title: A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
  • Publication Number: 3137
  • Session: 642. CLL: Therapy, excluding Transplantation: Poster III
  • Date and Time: Monday, December 7, 2020; 7:00 AM – 3:30 PM (Pacific Time)
  • Presenter: Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester Medical Center, NY
• Poster Presentation Title: Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
  • Publication Number: 1130
  • Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
  • Date and Time: Saturday, December 5, 2020; 7:00 AM – 3:30 PM (Pacific Time)
  • Presenter: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia

Following each presentation during ASH 2020, the data presented will be available on TG’s corporate website at http://tgtxinc.com/publications.cfm. TG abstracts are publicly available via the ASH meeting website at www.hematology.org or on the company’s corporate website. 

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as “U2”, targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. Umbralisib (TGR-1202) is an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib is currently under review by the U.S. Food and Drug Administration (FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen or follicular lymphoma (FL) who have received at least two prior systemic therapies. The Company also has a fully enrolled Phase 3 clinical trial evaluating U2 in patients with treatment naïve and relapsed/refractory chronic lymphocytic leukemia (CLL), and two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis (RMS).  Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially include the following:  the risk that interim, top-line, or other early clinical trial results, that may have supported the acceptance of our data for presentation or influenced our decision to proceed with additional clinical trials, will not be reproduced in final data sets or in future studies; the risk that we will not be able to meet the regulatory submission or clinical trial timelines that we project or achieve other anticipated milestones, including the risk that the evolving and unpredictable COVID-19 pandemic delays achievement of those milestones; and the risk that our compounds will not receive regulatory approval or become commercially successful products.. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:
	Jenna Bosco Senior Vice President, Corporate Communications TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]

• Tennessee-based Perimeter Pain and Primary Care Clinic is an established medical practice servicing over 12,000 patients per year.
• In 2019, the clinic generated CAD 2.2 million in revenues and CAD 400,000 in net income.
• Forecasted annual run rate now at over $20 million combined with the last 3 announced transactions.
• Skylight Health will pay a total cash consideration of CAD 1.03 million for the acquisition representing a 2.6x EBITDA multiple.
• This transaction will be immediately accretive to the Company adding complementary services and insurable revenue to the existing primary care model across 15 States.

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Skylight Health Group Inc (CSE:SHG; OTCQX: CBIIF) (“SHG” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has entered into a Letter of Intent (LOI) to purchase the assets of Healthcare Resources Management LLC (“HRM”) which operates Perimeter Pain and Primary Clinic (“Perimeter”) in Cookeville, Tennessee. The planned acquisition of HRM expands the Company’s bricks and mortar and telemedicine services to 15 States and will add 12,000 new patients to its current roster of 120,000.

HRM has been operating Perimeter in Cookeville for over 7 years with strong patient retention. Services to patients include primary care, chronic pain management, interventional procedures, weight management, regenerative medicine and aesthetics. Services provided by Perimeter are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors.

The Company expects to see continued growth in patient registrations and visits as Perimeter continues to thrive among the challenges most clinics have faced due to the recent COVID-19 pandemic. Further, the Company will work quickly to expand on the current offering of services by leveraging its current telemedicine infrastructure to provide access to patients across the state of Tennessee. Upon completion, services offered by Perimeter will apply to Skylight Health’s entire patient base. These services are immediately accretive as they allow the Company to expand complementary billable services. Patients will continue to benefit from the expansion of services in-house. The Company will benefit by expanding the per patient insurable revenue share-of-wallet by retaining these services internally.

“Perimeter represents the first of complementary non-primary care acquisitions and is in direct alignment with our strategy to expand on services offered to our existing patient base nationally,” said Prad Sekar, CEO, Skylight Health. “Adding vital services like chronic pain management, interventional procedures and other from Perimeter will benefit tens of thousands of our current patients and will be deployed nationally within the existing framework of payor contracts in each state we are organically establishing over the next year.”

HRM represents the fourth announced acquisition by the Company in the last 60 days. This acquisition supports and strengthens the 3-prong growth model which includes growth from the current infrastructure, new services and acquisitions. The Company will pay as per the agreed upon terms of the LOI, a transaction value in cash of CAD 1.03 million representing an EBITDA multiple of 2.6x. Perimeter reported revenues in 2019 of CAD 2.2 million and net income of CAD 400,000. This transaction is subject to a satisfactory due diligence period by the Company and mutual agreement to an Asset Purchase Agreement and Closing Conditions. The transaction is expected to close on or before December 31, 2020.

The Company also announces the grant of 3,176,000 options to the directors and senior officers. Options have been granted as of the close of business December 2, 2020 at a strike price of $0.77 with no discount. The Company has also issued 125,000 shares at a price of $0.62 to certain consultants for services delivered.

About Skylight Health Group

Skylight Health Group (CSE:SHG OTCQX:CBIIF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state health network that comprises of physical multi-disciplinary medical clinics providing a range of services from primary care, sub-specialty, allied health and laboratory/diagnostic testing. The Company owns and operates a proprietary electronic health record system that supports the delivery of care to patients via telemedicine and other remote monitoring system integrations. healthcare services. With a patient roster of over 120,000 patients, the Company’s operations spread across 14 states and continues to expand in services and locations both organically and by way of strategic acquisitions.

The Company primarily operates a traditional insurable fee-for-service model contracting with Medicare, Medicaid and other Commercial Payors. The Company also offers a disruptive subscription-based telemedicine service for the un/under-insured population who have limited access to urgent care due to cost.

For more information please visit www.skylighthealthgroup.com or contact:

Investor Relations
Jonathan L. Robinson CFA
Oak Hill Financial
[email protected]
416-669-1001

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Company’s unaudited financial results and projected growth.

Although Skylight Health as attempted to identify important factors that could cause actual results, performance or achievements to
differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced that it is recruiting ahead of schedule and has completed enrollment of the patients necessary for the interim data readout in the Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. The interim data readout will include initial safety and efficacy data for the first 113 patients enrolled in the trial. EDP1815 is an investigational oral biologic in development for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19.

“We are encouraged by the physician and patient interest in our Phase 2 trial, which has enabled us to complete enrollment to the interim target ahead of schedule despite the ongoing COVID-19 pandemic,” said Duncan McHale, M.B.B.S., Ph.D., Chief Medical Officer of Evelo. “Based on recent interactions with key opinion leaders, we see a growing understanding of the potential of SINTAX™ medicines to resolve systemic inflammation without immunosuppression, anticipating that EDP1815 may offer an improved profile over existing products and others in development as an orally-administered, safe, and effective medicine to address the needs of the millions of people with psoriasis.”

EDP1815-201 is a double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in 225 patients with mild to moderate psoriasis over a 16-week treatment period. The primary endpoint is mean reduction in Psoriasis Area and Severity Index (PASI) score at 16 weeks. Key secondary endpoints include other clinical measures of disease such as Physician’s Global Assessment (PGA), Body Surface Area (BSA), PGA x BSA, Psoriasis Symptom Inventory (PSI), Dermatology Life Quality Index (DLQI), and Lesion Severity Score (LSS).

About EDP1815 in Psoriasis

EDP1815 is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is a strain of Prevotella histicola, selected for its specific pharmacology. In the second and third quarter of 2019, Evelo reported positive Phase 1b interim clinical data in two cohorts of patients with mild to moderate psoriasis. EDP1815 was well tolerated at both doses, with no overall difference reported from placebo. There was a reduction in mean LSS and PASI score after 28 days of dosing in both cohorts who received EDP1815. In the high dose cohort alone, there was a continued reduction in both mean LSS (of 24% vs. placebo of 7%) and PASI score (of 21% vs. placebo of 3%) at 42 days – 14 days following the last dose of the drug. This may indicate a sustained clinical effect and dose response. EPD1815 was also observed to limit the systemic production of multiple inflammatory cytokines, including IL-6, IL-8, TNF, and IL-1, which are well-established mediators of potentially harmful effects in patients with inflammatory diseases.

About Psoriasis

Psoriasis is a common chronic immune-mediated inflammatory skin disease, affecting up to 3% of the population worldwide. The disease is driven by Th17-inflammation, which results in the formation of thickened red plaques with scaling. Psoriatic lesions can appear anywhere on the body but are most often seen on the knees, elbows, scalp, and lumbar area. There is a strong association with psoriatic arthritis, depression, and metabolic syndrome.

Patients with mild to moderate psoriasis are underserved by current treatments, including topical therapies, which do not control systemic inflammation, have low rates of compliance, or in the case of potent topical steroids, are not recommended for long-term use. The majority of novel therapies, including injectable high-cost biologics, are only approved for patients with moderate to severe disease. Even in this patient population, the majority of eligible patients do not receive biologics, instead opting for topical or oral systemic therapies, which are associated with tolerability issues and/or with monitoring requirements tied to safety concerns.  

About Evelo Biosciences

Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has five product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the timing and results of any clinical trials or readouts for EDP1815, our development plans, and the promise and potential impact of EDP1815 or our other product candidates.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our reliance on third parties and collaborators to expand our microbial library, conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; our management and principal stockholders have the ability to control or significantly influence our business; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended
September
30, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contact

Evelo Biosciences
Jessica Cotrone, 978-760-5622
[email protected]

TORONTO, Dec. 03, 2020 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV), the largest gaming platform in North America, reaching over 300 million monthly video game and esports fans worldwide, today announced that it has observed significant growth across a number of key metrics during Black Friday Week, representing the seven-day period from November 24 – 30, 2020, as compared to the corresponding period in 2019 (November 26 – December 2, 2019).

Black Friday is an important event in the digital media industry as there is typically a surge in the demand of digital ad inventory throughout the corresponding week. The Company is pleased to report the following observations for Black Friday Week 2020 vs 2019:

• 36% growth of total advertising revenue, including programmatic advertising revenue growth of 28%
• 12% increase in site views, resulting in nearly 800 million web and video content views in one week
• An additional 2,000 paid subscribers added to the Company’s web properties, representing an approximately 2% increase in monthly recurring subscribers gained in one week

“More and more brands are realizing the untapped value of our gaming and esports platform as an ideal advertising and engagement method to reach the Gen Z and millennial audiences,”
said Adrian Montgomery, CEO of Enthusiast Gaming.
“We are seeing strong growing numbers across our various segments which is a testament to the investments and strategic decisions we undertook during the past year including in ad tech, direct sales, content and distribution. We remain excited and confident about our growth trajectory.”

These results come on the heels of a successful virtual-only EGLX 2020, the fifth annual gaming festival which saw upwards of 12 million viewers across the globe and was supported by key sponsors G Fuel, SpiderTech and TikTok.

About Enthusiast Gaming

Enthusiast Gaming (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is building the world’s largest social network of communities for gamers and esports fans that reaches over 300 million gaming enthusiasts on a monthly basis. Already the largest gaming platform in North America and the United Kingdom, the Company’s business is comprised of four main pillars: Esports, Content, Talent and Entertainment. Enthusiast Gaming’s esports division, Luminosity Gaming, is a leading global esports franchise that consists of 7 professional esports teams under ownership and management, including the Vancouver Titans Overwatch team and the Seattle Surge Call of Duty team. Enthusiast’s gaming content division includes 2 of the top 20 gaming media and entertainment video brands with BCC Gaming and Arcade Cloud, reaching more than 50MM unique viewers a month across 9 YouTube pages, 8 Snapchat shows and related Facebook, Instagram and TikTok accounts. Its 100 gaming-related websites including The Sims Resource, Destructoid, and The Escapist collectively generate 1.1 billion page views monthly. Enthusiast’s talent division works with nearly 1,000 YouTube creators generating nearly 3 billion views a month working with leading gamer talent such as Pokimane, Flamingo, Anomaly, and The Sidemen. Enthusiast’s entertainment business includes Canada’s largest gaming expo, EGLX (eglx.com), and the largest mobile gaming event in Europe, Pocket Gamer Connects (pgconnects.com). For more information on the Company visit enthusiastgaming.com. For more information on Luminosity Gaming visit luminosity.gg.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking statements in this news release include, but are not limited to statements relating to the Enthusiast Gaming’s future growth in periods of increased market advertiser demand.

Forward-looking statements are based on assumptions, including expectations and assumptions concerning: interest and foreign exchange rates; capital efficiencies, cost saving and synergies; growth and growth rates; the success in the esports and media industry; and the Company’s growth plan. While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks related risks associated with general economic conditions; adverse industry events; future legislative, tax and regulatory developments. Readers are cautioned that the foregoing list is not exhaustive and other risks set out in Enthusiast Gaming public disclosure recorded filed under the Company’s provide on www.sedar.com, including those contained in the prospectus. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of Enthusiast Gaming which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:
Enthusiast Gaming – Eric Bernofsky
Chief Corporate Officer
[email protected]

Media Relations – ID 
[email protected]

Rogers provides phones and plans to women in crisis; extends previously donated plans by six months with second wave of pandemic

New partnership with
Fédération des maisons d’hébergement pour femmes
,
Regroupement des maisons pour femmes victimes de violence conjugale, and
Alliance des maisons d’hébergement de 2^e étape pour femmes et enfants victimes de violence conjugale

MONTREAL, Dec. 03, 2020 (GLOBE NEWSWIRE) — Deep into the second wave of COVID-19, Rogers Communications today announced it is providing hundreds of free phones, voice and data plans to women’s shelters across Quebec to enable connectivity for women experiencing violence and abuse. A recent report shows that since the start of the pandemic, the severity of violence against women seeking shelters has doubled, causing an urgent need to support women and children who may be facing the reality of being at home with an abusive family member.

“For Quebec women and children escaping abuse, phones and connectivity provide an essential digital lifeline that allows them to access emergency resources safely,” said Edith Cloutier, President of Quebec, Rogers Communications. “When home is no longer a safe place to be, we’re proud to help enable these critical connections for women and children so they can access critical resources from the organizations that support them.”

Expanding on a previous announcement with Quebec women’s shelters like L’Arrêt-Source and Le Chaînon in Montreal last spring, Rogers is providing hundreds of additional phones along with six months of free voice and data plans to women’s shelters across the province. The company is extending all services to the end of June 2021 to bridge connectivity needs as women are experiencing increased isolation during the second COVID-19 wave, with restrictions across Quebec.

Quebec women’s shelters receiving phones and plans include L’Inter Elles in Langelier, Maison Simonne Monet-Chartrand in Chambly, La Maison d’hébergement L’Égide in La Prairie, Le Havre des Femmes in L’Islet, La maison d’Athena in Montréal, Maison secours aux femmes in Montréal, La Clé sur la Porte in St-Hyacinthe,L’Ombre-Elle in Sainte-Agathe-des-Monts, Regroup’elles in Terrebonne, and Havre l’Éclaircie in St-Georges.

“It is crucial for women victims of violence, regardless of the region across Quebec, to be able to communicate easily and quickly with their loved ones, but also to stay in contact with shelter teams in case of need or danger,” said Manon Monastesse, Executive Director, Fédération des maisons d’hébergement pour femmes. “All the more so in this time of the pandemic, during which it is advisable to stay at home and go out as little as possible. Phones are tools that allow women to communicate securely and discreetly with shelters.”

“We know that the pandemic has had a significant impact on women,” said Mathilde Trou, co-responsible for political issues, Regroupement des maisons pour femmes victimes de violence conjugale. “Thanks to these cell phones, the women in our care and staying in our shelters will be able to stay in touch with their loved ones and continue their efforts, without having to worry about the minutes they have left on their phone. This is invaluable help and will be greatly appreciated.”

“A phone is a crucial link for isolated women to maintain contact with their loved ones and our support services during the pandemic,” said Gaëlle Fedida, Political Affairs Coordinator, Alliance des maisons d’hébergement de 2^e étape pour femmes et enfants victimes de violence conjugale. “Having safe phone lines at their disposal, ones that are unknown to their abusive spouse, allows women to concretely move forward towards a new life without violence.”

If you are a woman living in an abusive home, or you know someone who is, you can call your local shelter’s 24/7 crisis line for advice and support. Find your local shelter and its crisis line on sheltersafe.ca/quebec.

In addition to today’s announcement, Rogers previously announced donations of 300 phones and plans to keep Quebec youth connected to mentors. These services have been extended by another six months to bridge connectivity needs during this second wave of COVID-19. This includes phones and plans to organizations like Big Brothers Big Sisters of Greater Montreal to allow “Littles” to stay in regular contact with their “Bigs”, Pflag Montreal for virtual peer mentoring sessions for LGBTQ2S+ youth and their families, and for virtual youth education programs offered by YMCA of Quebec and the Fondation pour les élèves de la Commission scolaire de la région de Sherbrooke.

About Rogers

Rogers is a proud Canadian company dedicated to making more possible for Canadians each and every day. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. We have grown to become a leading technology and media company that strives to provide the very best in wireless, residential, sports, and media to Canadians and Canadian businesses. Our shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). If you want to find out more about us, visit about.rogers.com.

For more information:

Rogers Communications, [email protected], 1-844-226-1338

RXMD Management to Discuss Details Regarding Recently Filed Proxy Statement and Address Shareholder Questions Submitted in Advance

MIAMI, Dec. 03, 2020 (GLOBE NEWSWIRE) — via NewMediaWire – Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, is pleased to announce that the Company has scheduled an investor conference call for 4:30 PM ET on Monday, December 7, 2020.

The Company will address the recently filed proxy statement. In addition, interested parties can submit questions concerning the Company to Stuart Smith at SmallCapVoice.Com, Inc. via email: [email protected] by 5:00 PM ET on Friday, December 4, 2020. In determining the questions that will be addressed, the Company will use its discretion, considering factors such as relevance to the entire shareholder base and appropriateness in light of compliance requirements under applicable securities laws.

To access the call:

Dial-In Number: 1-857-232-0157 Access Code: 422095

For those unable to participate in the live conference call, a replay will be available at https://www.smallcapvoice.com/clients/rxmd/ shortly after the call has concluded. An archived version of the webcast will also be available https://www.progressivecareus.com/news-releases.

Connect and stay in touch with us on social media:

Progressive Care Inc. 
https://www.facebook.com/ProgressiveCareUS/https://twitter.com/ProgressCareUS

PharmCo Rx 
https://www.facebook.com/pharmcorx/https://twitter.com/PharmCoRx

ClearMetrX

https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/

Progressive Care Inc. (RXMD), through its subsidiaries, is a Florida technology and health services organization that provides prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management. Cautionary Statement Regarding Forward-Looking Statements: Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:

Carlos Rangel
[email protected]
www.progressivecareus.com
www.pharmcopharmacy.com

For SmallCapVoice.com, Inc.

Stuart T. Smith 512-267-2430
[email protected]
www.SmallCapVoice.com

DALLAS, Dec. 03, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, such as CBD, CBG, and CBN, announced today that it has selected Accent Clinical Research Professionals, LLC (”ACCENT”) of Allen, Texas to administer RTSL’ first round of human research of its proprietary CBD and CBG blended MDI. RTSL expects to sign the formal agreement by December 31, 2020.

ACCENT is a clinical research center, specializing in Phase I-IV pharmaceutical and device studies dedicated to providing high quality and reliable research data to sponsors striving to advance today’s medicine while rigorously maintain the safety of patients. The principal investigator of the MDI for the clinical trials is Dr. Neal C. Lawrence, M.D. and Dr. Charles L. Powell, M.D. will be the medical advisor to RTSL.

RTSL’s CEO, Donal R. Schmidt, Jr. states, “Our decision to go with Accent (www.amrprofessionals.com) and the two physicians we chose was quite simple. Accent is known for quality and integrity which has made them a preferred provider for some of the largest pharmaceutical companies. In addition, both physicians are active in research and thoroughly believe in the long-term potential of cannabinoids for use in conjunction with modern treatment modalities. And finally, this team gives RTSL access to a patient pool of over 150,000 trial candidates in the DFW Metroplex with more than ten (10) years of medical data per disease indication.

We intend to run an eight (8) leg study looking at support for anxiety, chronic pain, ADHD, inflammation (this will include COVID-19 pulmonary rehabilitation and recovery), arthritis, insomnia, and depression. We are also discussing testing on “long-haul” Covid-19 recovery patients as well. Each study will have 50 volunteer patients with significant documented disease histories going back more than a decade. The initial protocols will focus on both objective and subjective results which will then be further narrowed for the next round of testing. Eventually, we will narrow our focus to normalize dosage relative to blood plasma levels of each cannabinoid or blend thereof.”

About Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)

RTSL has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formulae consisting of one or more cannabinoid compounds, such as CBD, CBG, and/or CBN. The Company’s Rxoid™ and nhāler product lines are manufactured in compliance with Good Manufacturing Practices (GMP), on FDA-listed equipment. Note that while cannabinoids such as CBD, CBG and CBN are not yet approved by the FDA, under the laws of Texas and of many other states, it is legal to consume, sell and export them to legal jurisdictions.

Properly formulated MDI deliver Active Pharmaceutical Ingredients (API) (drugs, nutraceuticals or bioceuticals) through the pulmonary tract. An MDI is generally the most efficient delivery method for an API other than an IV. In addition, MDIs are less expensive than any other route of delivery, based on the net cost per bioactive mg as tested in blood serum levels. However, MDIs are expensive to formulate and difficult to manufacture in order to deliver cannabinoid compounds to the level required by the FDA and FTC truth in labelling laws. Ideally, a properly formulated, properly manufactured MDI containing cannabinoids will deliver exactly the same dose on its first use as well as its 100th use.

RTSL’s MDIs are a safe and technically superior replacement for vape pens, mods and all-in-one products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98% bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows RTSL to manufacture a scientifically sound and superior alternative to all other cannabinoid vaping systems in a market estimated to be $5 billion in annual sales.

RTSL products will continue to be sold directly to pharmacies, physicians and other healthcare providers who treat GAD, PTSD and other stress and anxiety disorders. nhāler can be purchased online at www.nhaler.com. Rxoid™ currently is unavailable to purchase as its website is being updated. RTSL also produces white label products for select commercial clients.

Now RTSL is entering into the quickly evolving medical grade isolate manufacturing space. RTSL will manufacture CBD, CBG, CBN, and various other minor cannabinoids and terpenes under proprietary processes as it increases its ever growing list of formulas for support of various treatment regiments that physicians and health care providers are beginning to recommend in conjunction with more traditional mainstream medications

We encourage all individuals to do their own research regarding cannabinoids, the use of MDI and our products. RTSL makes no claims about therapeutic benefits of its products. None of our products are intended to diagnose, treat, cure, or prevent any disease. Always consult a physician prior to using any cannabinoid product. If you experience any adverse reaction stop use immediately and seek appropriate medical attention. RTSL’s products are not approved by the FDA or under the Food Drug & Cosmetics Act (FD&C Act).

Visit our corporate website at www.rtslco.com.

Forward-Looking Statements 

This press release may contain forward-looking statements. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of RTSL, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in filings made by RTSL with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which we have filed, and file from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on RTSL’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. RTSL cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contact:
Donal (Don) R. Schmidt, Jr.
Chairman and CEO
[email protected]

Phone: 800-497-6059
Fax: 877-676-8527

EATONTOWN, N.J., Dec. 03, 2020 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor, will begin to distribute SUSE’s innovative open source solutions including a best-in-class Linux operating system, a market-leading Kubernetes management platform and a host of pioneering edge capabilities. SUSE is committed to providing dependable, adaptable, and highly flexible open source solutions for the most demanding IT environments.

Modern data centers have become increasingly complex and filled with several different products. Every data center not only needs these products to work, but also needs them all to work well together seamlessly. SUSE’s work with its ecosystem of partners and communities support its delivery of truly open, open source solutions.

“SUSE has entered a new phase of partnerships following the launch of the SUSE One Partner Program in September 2020,” said Joel Petlick, Director of Americas Channel at SUSE. “This streamlined program was created and aligned to fit the needs and expectations of our partner community, all to support partner profitability and joint growth. As a global leader in true open source innovation, SUSE offers customers choices that helps them avoid vendor lock-in and fosters innovation. Climb is an ideal fit for our expansion by introducing SUSE to a partner base that’s emerging-technology focused and providing distribution support that’s agile and committed to our joint success. With Climb, we offer a new element of choice to partners and their customers.”

SUSE works with partners around the globe to bring cutting-edge, SUSE-compatible technology to provide customers options that perfectly fit their needs. These partnerships allow SUSE to power digital transformation for the enterprise by simplifying, modernizing and accelerating traditional cloud and edge solutions.

“SUSE’s flexible business practices, lack of vendor lock -in and exceptional service have given us a great deal of confidence in our partnership,” said Dale Foster, CEO of Climb Channel Solutions. “The addition of SUSE allows us to provide technology that’s both innovative and complementary, along with a full suite of training, consultation, and support solutions to our resellers.”

Those interested in distribution services and solutions should contact Climb by phone at +1.800.847.7078 (US), or +1.888.523.7777 (Canada), or by email at [email protected].

About
Climb Channel Solutions

Climb Channel Solutions, a subsidiary of Wayside Technology Group, Inc. (NASDAQ: WSTG), is an international specialty technology distributor focused on emerging technologies. Climb provides partners with access to Security, Data Management, Virtualization and Cloud, Storage and Hyperconverged Infrastructure, Connectivity, Software and Application Lifecycle, and other technically sophisticated products. The company helps vendors recruit and build multinational solution provider networks, power their networks, and drive incremental sales revenues that complement existing sales channels. Climb services thousands of solution providers, VARs, systems integrators, corporate resellers, and consultants worldwide, helping them power a rich opportunity stream while building profitable businesses.

For additional information visit www.climbcs.com, or call 1.800.847.7078 (US), +1.732.389.0037
(International), +1.888.523.7777 (Canada), or +31.20.210.8005 (Europe).

Follow Climb Channel Solutions on Facebook, LinkedIn and Twitter.

– No unexpected
safety findings
during the course of
the study
–

–
On track to file
an
IND by end of year; Phase 1 clinical trial to commence in early 2021 –

WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert^® technology for wet age-related macular degeneration (wet AMD).

Results from the study showed no EYPT-1901-related adverse ocular or systemic toxicology findings at any dose level studied in the rabbit model. There were no changes in key ocular measurements such as intraocular pressure (IOP) and no changes in liver function enzymes as is often seen with systemic delivery of tyrosine kinase inhibitors. These results provide additional rationale for the advancement of EYP-1901 into clinical development.

“We continue to believe in the potential of EYP-1901 to be a disruptive and beneficial treatment option for patients and physicians for the long-term treatment of wet AMD. These promising safety results reinforce the potential product profile of EYP-1901 and will be included in our Investigational New Drug (IND) submission that is expected to be filed before the end of the year,” said Jay Duker, M.D., Chief Strategic Scientific Officer of EyePoint Pharmaceuticals. “Upon IND allowance by the U.S. Food and Drug Administration (FDA), we plan to rapidly initiate our Phase 1 clinical trial of EYP-1901 and dose our first patient in early 2021.”

About
EYP-1901

EYP-1901 is a potential six-month sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 combines EyePoint’s proprietary bioerodable Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib has established efficacy signals observed in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events reported. Preclinical studies of EYP-1901 administered locally into the eye have shown promising anti-VEGF activity with no serious safety issues observed. EyePoint plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2020 and expects to initiate a Phase 1 trial in early 2021. EYP-1901 is initially being developed as a treatment for wet AMD, with the potential for future indications in diabetic retinopathy and retinal vein occlusion.

About
EyePoint
Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the extent to which our business could be adversely impacted by the effects of the COVID-19 coronavirus pandemic, as well as the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a vital, novel six-month treatment for wet age-related macular degeneration. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera’s ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera’s ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; our ability to market and sell products; the success of current and future license agreements, including our agreement with Equinox Science; termination or breach of current license agreements, including our agreement with Equinox Science; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contacts

Investors:
Argot Partners
Sam Martin or Joe Rayne
212-600-1902
[email protected]

Media:
Thomas Gibson
201-476-0322
[email protected]